Advancing Tobacco Use Treatment for African American Smokers

Completed · Phase 4 · Has a placebo group

Conditions studied: Smoking Cessation

In brief

The purpose of this study is to examine whether or not providing Chantix (varenicline) will help African American smokers quit smoking.

Key facts

Study ID

NCT02360631

Run by

Lisa Sanderson Cox, PhD

People needed

500

Starts

2015-07-29

Expected to finish

2018-07-12

Last updated by the study team

2020-07-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Self-identified African American
• Smokes ≥ 1 cigarette per day (cpd)
• Smoke on ≥ 25 days of the past 30 days
• Functioning telephone
• Interested in quitting smoking
• Interested in taking 3 months of varenicline
• Willing to complete all study visits

You may not qualify if…

• Renal impairment
• Evidence or history of clinically significant allergic reactions to varenicline
• A cardiovascular event in the past month
• History of alcohol or drug dependence in the past year
• Major depressive disorder in the last year requiring treatment
• History of panic disorder, psychosis, bipolar disorder, or eating disorders
• Use of tobacco products other than cigarettes in past 30 days
• Use of pharmacotherapy in the month prior to enrollment, including prior use of varenicline
• Pregnant, contemplating getting pregnant, or breastfeeding
• Plans to move from Kansas City during the treatment and follow-up phase
• Another household member enrolled in the study
• Evidence of current severe major depressive disorder or suicidal ideation

Where it is running

• University of Kansas Medical Center — Kansas City, Kansas, United States
• Swope Health Central — Kansas City, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.